This study investigates low-grade glioma and pancreatic cancer with BRAF fusion or rearrangement. The purpose of this study is to evaluate an investigational medication in patients with these conditions.
The study evaluates the safety and efficacy of the investigational medication in patients with specific genetic markers. It focuses on understanding how well patients tolerate the treatment and any effects it may have.
- Who can participate: Adults and children aged 12 years and older with low-grade glioma or pancreatic cancer may participate. Key eligibility includes having a BRAF fusion or rearrangement and measurable disease.
- Study details: Participants will take an investigational medication orally. Some may receive a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.